Effects of CFTR Modulators on Serum Biomarkers of Liver Fibrosis in Children with Cystic Fibrosis

Steven Levitte; Yonathan Fuchs; Russell Wise; Zachary M. Sellers

doi:10.1101/2022.09.02.22279547

ABSTRACT

The cystic fibrosis transmembrane conductance regulator (CFTR) corrector/potentiator combinations lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor improve sweat chloride, pulmonary function, and nutrition. Yet it is unclear whether they may also impact the progression of liver fibrosis, which is a substantial source of morbidity and mortality for patients with cystic fibrosis (CF). We conducted a retrospective, single-center analysis of children and adolescents with CF treated with lumacaftor/ivacaftor and/or elexacaftor/tezacaftor/ivacaftor therapy, focusing on alterations in liver function tests and fibrosis indices using previously-established thresholds that corresponded with increased liver elastography. In pairwise comparisons of before and during treatment timepoints, we found that those with CF-associated liver involvement experienced significant decreases in gamma-glutamyl transferase (GGT), AST-to-Platelet Index (APRI), and GGT-to-Platelet Ratio (GPR) while on lumacaftor/ivacaftor. These differences were not observed in patients treated with elexacaftor/tezacaftor/ivacaftor, nor were they observed in patients without underlying CF-associated liver disease. These results provide the first evidence that lumacaftor/ivacaftor may improve liver fibrosis in children and adolescents with CF and suggest it may be beneficial in the treatment of CF-associated liver disease.

Competing Interest Statement

ZMS is a paid consultant for Vertex Pharmaceuticals, but has no financial interest in the company. Vertex had no involvement in any aspect of the research (including funding, study design, or access to the data).

Funding Statement

Funding provided by the Cystic Fibrosis Foundation (SELLER16L0, SELLER19GE0, SELLER20A0-KB to Z.M.S), National Institute of Diabetes and Digestive and Kidney Diseases (K08DK124684 to Z.M.S.), and Stanford University (Z.M.S). Funding sources were not involved in the study design.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Stanford University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Conflicts of Interest: ZMS is a paid consultant for Vertex Pharmaceuticals, but has no financial interest in the company. Vertex had no involvement in any aspect of the research (including funding, study design, or access to the data).
Funding: Funding provided by the Cystic Fibrosis Foundation (SELLER16L0, SELLER19GE0, SELLER20A0-KB to Z.M.S), National Institute of Diabetes and Digestive and Kidney Diseases (K08DK124684 to Z.M.S.), and Stanford University (Z.M.S). Funding sources were not involved in the study design.